biostudies-literatureFarooq SNIHRNational Institute for Health Research (NIHR)e056420https://www.ebi.ac.uk/biostudies/studies/S-EPMC8996048biostudies-literatureUnknown12(4)<h4>Introduction</h4>Treatment-resistant schizophrenia (TRS) is associated with significant impairment of functioning and high treatment costs. Identification of patients at high risk of TRS at the time of their initial diagnosis may significantly improve clinical outcomes and minimise social and functional disability. We aim to develop a prognostic model for predicting the risk of developing TRS in patients with first-episode schizophrenia and to examine its potential utility and acceptability as a clinical decision tool.<h4>Methods and analysis</h4>We will use two well-characterised longitudinal UK-based first-episode psychosis cohorts: Aetiology and Ethnicity in Schizophrenia and Other Psychoses and Genetics and Psychosis for which data have been collected on sociodemographic and clinicBMJ openStudy protocol for the development and internal validation of Schizophrenia Prediction of Resistance to Treatment (SPIRIT): a clinical tool for predicting risk of treatment resistance to antipsychotics in first-episode schizophrenia.PMC8996048NIHR 200510PDF-2018-11-ST2-020van der Windt DNettis MARiley RHattle MAjnakina OFarooq SDazzan PKingstone TShiers DLawrence AfalseStudy protocol for the development and internal validation of Schizophrenia Prediction of Resistance to Treatment (SPIRIT): a clinical tool for predicting risk of treatment resistance to antipsychotics in first-episode schizophrenia.<h4>Introduction</h4>Treatment-resistant schizophrenia (TRS) is associated with significant impairment of functioning and high treatment costs. Identification of patients at high risk of TRS at the time of their initial diagnosis may significantly improve clinical outcomes and minimise social and functional disability. We aim to develop a prognostic model for predicting the risk of developing TRS in patients with first-episode schizophrenia and to examine its potential utility and acceptability as a clinical decision tool.<h4>Methods and analysis</h4>We will use two well-characterised longitudinal UK-based first-episode psychosis cohorts: Aetiology and Ethnicity in Schizophrenia and Other Psychoses and Genetics and Psychosis for which data have been collected on sociodemographic and clinic2022-01-01T00:00:00Z2022 Apr2025-04-22T07:47:30.243Z2025-04-05T22:18:10.497ZS-EPMC89960483539629410.1136/bmjopen-2021-056420